Thursday, November 6, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analyst Expresses Optimism and Raises Price Target for Endava Stock

Elaine Mendonca by Elaine Mendonca
January 17, 2024
in Breaking News
0
Technology Blockchain Trading online
0
SHARES
1
VIEWS
Share on FacebookShare on Twitter

On January 17, 2024, Ashwin Shirvaikar, an analyst at Citigroup, expressed his optimistic stance on Endava (NYSE:DAVA). Shirvaikar reiterated a Buy rating on the company’s stock and increased the price target from $70 to $90. This upward revision in the price target signifies the analyst’s positive outlook on the company’s future growth potential.

Shirvaikar believes that Endava’s stock is currently undervalued and has the capability to reach the new price target of $90 in the coming period. This suggests that the company may experience significant growth in the future.

In addition to Shirvaikar’s analysis, other analysts have also provided their price targets for Endava. The consensus average among these analysts stands at $74.00, with price targets ranging from $70.00 to $83.00. This indicates a general agreement among analysts regarding the positive trajectory of Endava’s stock.

Overall, the revised price target of $90 set by Ashwin Shirvaikar highlights the potential for growth in Endava’s stock, reinforcing the positive sentiment surrounding the company’s future prospects.

DAVA Stock Price Suffers Slight Decline on January 17, 2024: Investors Advised to Exercise Caution

On January 17, 2024, DAVA stock experienced a slight decline in its price momentum. The price of DAVA shares decreased by $0.26 since the market last closed, representing a 0.34% drop. The stock closed at $77.15, indicating a slight decline in value compared to the previous trading session. After the market closed, the stock experienced a further drop of $0.61 in after-hours trading. It is unclear what factors contributed to this additional decline in value. Investors should exercise caution when interpreting after-hours trading data. Overall, the performance of DAVA stock on January 17, 2024, suggests a slight decline in value. Investors should conduct further research and analysis to gain a comprehensive understanding of DAVA’s performance and make informed investment decisions.

DAVA Stock Performance on January 17, 2024: Revenue Growth and Profitability Concerns

Title: DAVA Stock Performance on January 17, 2024: A Closer Look

Introduction:
On January 17, 2024, DAVA stock witnessed mixed performances, reflecting both positive and negative trends. This article will delve into the stock’s financials, focusing on its total revenue, net income, and earnings per share (EPS) figures.

Total Revenue:
DAVA’s total revenue for the past year stood at $955.89 million, marking a 9.84% increase compared to the previous year. However, the total revenue remained flat at $238.44 million for the first quarter of the current fiscal year.

Net Income:
In terms of net income, DAVA reported $113.26 million for the previous year, indicating no change from the prior year. However, the net income experienced a significant decline of 45.79% during the first quarter, falling to $15.65 million.

Earnings per Share:
DAVA’s earnings per share (EPS) stood at $1.95 for the past year, demonstrating no change compared to the previous year. However, the EPS experienced a substantial decrease of 45.94% during the first quarter, dropping to $0.27.

Analysis:
DAVA’s total revenue performance showcases a positive growth trend over the past year, with a notable increase of 9.84%. However, the flat total revenue in the first quarter suggests that DAVA may have encountered challenges or experienced a slowdown in its business activities during that period.

On the other hand, DAVA’s net income figures present a mixed picture. While the net income remained unchanged compared to the previous year, it experienced a significant decline of 45.79% during the first quarter. This decline could be attributed to various factors, such as increased expenses, changes in market dynamics, or other internal or external factors affecting the company’s profitability.

Similarly, DAVA’s EPS figures indicate a flat performance over the past year, with no change compared to the previous year. However, the first quarter witnessed a substantial decline of 45.94% in EPS. This decline suggests that DAVA’s profitability per share has been negatively impacted, possibly due to the aforementioned factors affecting net income.

Conclusion:
DAVA’s stock performance on January 17, 2024, reflects a mixed bag of results. While the company experienced positive growth in total revenue over the past year, the first quarter’s flat revenue indicates a potential slowdown. Moreover, the decline in net income and EPS during the first quarter raises concerns about DAVA’s profitability. Investors and analysts will closely monitor future financial reports to assess the company’s ability to overcome these challenges and sustain its growth trajectory.

Tags: DAVA
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Alternative Energy Stock Market Today

Analysts Ratings and Price Targets for DT Midstream

Bristol Myers Squibb Presents Groundbreaking Research on Genitourinary Cancer Treatment at ASCO GU 2024

Biotechnology Markets and money

Mixed Analyst Views and Downward Trend in Price Target for Adtran NASDAQ ADTN

Recommended

EEFT stock news

Analyst Ratings and Price Targets for Definitive Healthcare

2 years ago
Healthcare Services Stock Exchange

Analyst Ratings and Price Targets for Inari Medical NASDAQNARI

2 years ago
STZ stock news

Analyzing Analyst Recommendations and Target Price for FirstEnergy Corp.

2 years ago
Healthcare-sector

Introducing the Revolutionary Herbalife GLP1 Nutrition Companion

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin BioNTech Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF NIO Nvidia Ocugen Opendoor Oracle Oxford Lane Capital Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Molina Healthcare: Crisis or Opportunity as Legal Storms and a Legendary Investor Collide?

Nio’s Unprecedented Delivery Streak Fuels Profitability Push

Is 3M’s Resurgence Signaling a Sustainable Recovery?

Eastman Chemical’s Challenging Quarter: A Deep Dive into the Numbers

BioNTech’s Crossroads: Navigating Losses Amid Cancer Research Promise

China Lifts Export Ban on Illumina’s DNA Sequencers, Sparking Market Rally

Trending

MannKind Stock
Analysis

MannKind Shares Surge on Exceptional Quarterly Performance

by Robert Sasse
November 6, 2025
0

MannKind Corporation witnessed a substantial rally in its share price following the release of its third-quarter 2025...

Amgen Stock

Amgen’s Impressive Quarterly Performance Fuels Investor Confidence

November 6, 2025
Teledyne Stock

An Overlooked AI Contender Emerges in Defense Technology

November 6, 2025
Molina Healthcare Stock

Molina Healthcare: Crisis or Opportunity as Legal Storms and a Legendary Investor Collide?

November 6, 2025
Nio Stock

Nio’s Unprecedented Delivery Streak Fuels Profitability Push

November 6, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • MannKind Shares Surge on Exceptional Quarterly Performance
  • Amgen’s Impressive Quarterly Performance Fuels Investor Confidence
  • An Overlooked AI Contender Emerges in Defense Technology

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com